Hospital eating rebates are frequently reported Hunan a doctor report letter involving multiple drug rebate amounts

On October 13th, a post entitled "Reporting drug rebates from the People's Hospital of Yanning County" was widely circulated on the Internet.
reported that he is a doctor at the Yanning County People's Hospital, the reason for reporting the hospital to eat rebates, in order to purify the medical environment.
post shows that the hospital director XXX dereliction of duty, suspected of commercial bribery, while the big drug dealers contracted the hospital pharmacy, 98% of the hospital's drugs belong to the two big bosses.
, the rebates given by large drug dealers are: 10%-15%/branch of antibiotics, 10 yuan/branch of pentolatole needles, omeprazole needles;
and the rebate given by the small drug dealer is: Budnaid Fumotro powder inhaler 10%/branch, non-cloth he from 10 yuan / box to 8 yuan / box, sulfur aluminum 4 yuan / box, Reba Pait 3 yuan / box, aspirin intestinal solution tablets, tegrillo 6 yuan / box, Alishatan ester 7 yuan / box (last year's punch out of the rebate 22 yuan / box) whistleblower also clarified the rebate process.
drug dealers issue rebates every three months or six months, with monthly rebates ranged from 3,000 to more than 10,000 yuan depending on the position.
and the small drug dealer gives it once a month.
Working Group has been stationed in the investigation in response to the above-mentioned posts, Yanning County Health And Health Bureau on October 13 responded: Yanning County Health Bureau Party Committee attaches great importance to October 12 on the situation reflected in a special study, set up a special working group stationed in Yanning County People's Hospital, is currently under verification.
not uncommon for doctors to report their hospital eating rebates: last year, a doctor in Wanning, Hainan, reported himself and the hospital to eat kickbacks.
earlier, the director of a department of Longhua District People's Hospital in Shenzhen reported that doctors from 12 departments of his hospital were collectively taking drug rebates.
frequently appear in hospitals.
reports come not only from doctors and department directors, but also from pharmaceutical representatives and rival pharmaceutical companies.
October, several Sanjia hospitals in Anhui posted several anonymous letters of reporting.
the contents of these letters are approximately the same.
report letter pointed out that some of these hospital doctors and medical representatives have abnormal sales relations, there are problems with gold sales.
The report involves varieties from three well-known domestic pharmaceutical companies, including narcotic drugs, oncology drugs, etc. , the amount of rebates to doctors accounted for about 12% of the drug price, but also in the name of the conference to pay doctors lecture fees.
report indicates the drugs involved, the amount or proportion of rebates, the abnormal sales relationship between doctors and medical representatives, and the sale of gold.
“...... The production of anti-tumor drugs, retail price of 3409 yuan a box, cancer patients a month treatment costs 10227 yuan, the hospital oncologist, radiotherapy doctors actually take 400 rebates per box..." Oncology and radiotherapy department output from August 2018 to date, a total of more than 750 boxes, bribes up to more than 300,000.
"" Jiangsu... Limited Companies in the Hospital has imaging-related drugs, narcotics-related drugs, infection-related varieties, respiratory drugs, hematology drugs, oncology radiotherapy drugs, etc. , each selling a box of drugs, to prescription doctors 12% of the price of cash ..." Pharmaceutical group sales companies in the market, to its agents and market sales staff, take the product floor price and high rates, and instigate sales staff to medical institutions to promote the sale of gold, commercial bribery, in order to achieve sales performance, task indicators, take a series of illegal means across the compliance bottom line, and a Some medical institutions medical personnel formed a black chain of interests, covering a number of departments, etc. , to the doctor public relations, the implementation of bribery, kickbacks and other promotional means, so that doctors more drugs, over-prescription of drugs..." October 20, Xijing Hospital appeared a real-name report letter.
report letter related to medical device companies: Shaanxi United States and Australia medical supplies have the current company, Xi'an Zhuoyuan medical devices have the current company, Xi'an Bijuan medical devices have the current company, Xi'an Kyusju Tongmontein medical devices have the current company.
the above-mentioned companies have been in Xijing Hospital, orthopaedic hospital departments to provide medical equipment and other internal plant supplies, and to the department director, doctors to carry out commercial bribery.
The report letter also stated the operation process and specific amount of medical bribery: the company in the form of internal follow-up documents and bookkeeping amount (actually the invoice invoice amount) to the section director or department head of the unit for the current month's settlement.
commercial bribes to department directors and doctors at a rate of 20%-35% of the billable amount for a single operation.
patients pay 10,000 yuan per supplies, 20%-35% will be through the company's operations by the department directors and doctors to take away, the amount is particularly huge.
For whatever reason, compliance pressures are soaring across the pharmaceutical industry, and at this sensitive time, the letter appears to be at the right time, allowing gold sales to raise as much attention as possible and expanding the impact of medical corruption.
October 17th, the website of the Central Commission for Discipline Inspection published the contents of "Strictly checking the transaction of power and money, establishing a list of loss of trust, concentrating on volume procurement, and cutting off the chain of medical bribery benefits", referring directly to improper transactions between medical representatives and medical institutions.
September 2, the official website of the Central Commission for Discipline Inspection published the article "Taking cases as a mirror, Chengdu seriously rectifying corruption in the medical field", referring directly to medical personnel receiving red envelope gifts from management objects, using the convenience of their positions, and adopting illegal methods for relevant personnel in drug supply, equipment procurement for profit and other illegal and disciplinary acts.
August 25th, the inspection work meeting convened by the National Health and Health Commission and the 2020 inspection mobilization and deployment meeting of the Party Group of the Commission, the list of members of the inspection team, the list of the inspected party organizations and the inspection tasks were arranged, announcing that the hospital inspection entered a high-pressure period.
July 24, the National Health and Safety Commission issued a "notice on the issuance of the 2020 medical industry style construction work special action plan", clearly from July this year until the end of the year, will focus on the treatment of medical personnel to collect kickbacks, pharmaceutical companies illegal marketing and other acts.
June 5, the National Health and Wellness Commission and nine other departments jointly issued "2020 to correct the field of pharmaceutical purchase and sale and medical services in the field of the wrong wind work points", clear and serious investigation and punishment of the collection of pharmaceutical supplies enterprise rebate behavior.
recently, a series of pharmaceutical companies bribery cases, whistle-blowing letters were exposed, the entire pharmaceutical industry compliance pressure is soaring.
With the advance of national procurement, the development of tax verification in the pharmaceutical industry, as well as the two-vote system, health insurance fee control policy, coupled with a strict investigation of drugs, equipment supplies rebates, and crack down on medical corruption, the traditional drug marketing methods that used to rely on high pricing and channel space to drive sales will be completely subverted.
high-pressure market environment and huge conflicts of interest, the pharmaceutical industry will be full of whistle-blowing letters, pharmaceutical companies must be timely transformation.